Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MannKind Corporation (Nasdaq: MNKD) has appointed Lauren Sabella as Executive Vice President and Chief Operating Officer effective March 27, 2023. Reporting directly to CEO Michael Castagna, Sabella brings over 12 years of experience from Acorda Therapeutics, where she served as COO. Her previous roles include Chief Commercial Officer and Vice President of Commercial Development, contributing to significant product launches with peak sales exceeding $1 billion. Sabella will oversee critical operations in Danbury, focusing on expanding MannKind's endocrine business and preparing to launch new products in the orphan lung disease market.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 2:00 PM (ET). Interested parties can access the live webcast through the company's website, with a replay available for 14 days after the event.
MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices for effective medicine delivery. The company is committed to addressing medical needs related to diabetes and pulmonary diseases.